“Human data,” “clinical research,” and “clinical trial data” get used interchangeably online, but they describe different levels of evidence. A cell study isn’t a clinical trial, and neither is an animal study. Measuring a naturally occurring peptide in human blood isn’t the same as administering it experimentally. A registered trial isn’t the same as completed, published results, either.

This overview compares compounds across several evidence stages, spanning registered interventional studies with posted results and compounds with no verified registered intervention trial. Verifying these records independently matters, since registry statuses shift constantly.

What Counts as Clinical Trial Data?

An interventional clinical trial is a study in which participants are assigned to an intervention so researchers can evaluate its effects. ClinicalTrials.gov distinguishes interventional studies from observational studies, where participants are observed rather than assigned an intervention.

Several distinct evidence categories exist along that path for peptides in clinical trials:

• In vitro: cells, tissues, or biochemical systems, not living organisms.
• Animal / preclinical: nonhuman experimental models.
• Human observational: researchers measure variables in humans without assigning the peptide as an intervention.
• Human interventional trial: participants are assigned to receive an intervention.
• Registered trial: a public study record exists.
• Results-posted trial: structured results have been submitted to the registry.
• Peer-reviewed trial publication: findings appear in a scientific journal.

A peptide can have human data without having interventional clinical trial data. It can also have a registered clinical trial without having completed or published results. Treating those categories as interchangeable is where most confusion about peptide clinical trial data starts.

Which Research Peptides Currently Have Documented Human Trial Evidence?

For peptides in clinical trials, status must be rechecked immediately before publication, since registry records change continuously.

Compound	Registered human interventional trial?	Highest verified stage / status	Results available?	Evidence note
SS-31 / elamipretide	Yes	Multiple Phase 2/3 and Phase 3 programs	Yes, for some studies	Most mature clinical evidence among compounds covered here
BPC-157	Yes	Recruiting Phase 2 record as of 2026	No results yet from that trial	Human evidence otherwise remains limited
MOTS-c	Yes	Recruiting Phase 2a record as of 2026	No results yet	Separate administered-MOTS-c trials from studies that only measured endogenous MOTS-c
KPV	No verified registered interventional trial identified in this search	—	—	Recheck exact intervention name before publication
Other compounds	Verify individually	—	—	Do not infer status from related molecules

Researchers wanting broader context beyond trial status specifically can explore Certified Peptide Solutions’ peptide research library to compare mechanisms and preclinical evidence across individual compounds.

SS-31 / Elamipretide: The Most Clinically Developed Example in This Group

SS-31 is commonly associated with the clinical-development name elamipretide. Searching only “SS-31” can miss relevant records, which is exactly why synonym checking matters for ss-31 clinical trials.

The completed TAZPOWER study evaluated elamipretide in Barth syndrome as a randomized, double-blind, placebo-controlled crossover trial with an open-label extension (NCT03098797). The record is completed, and results have been publicized since April 2024.

A separate Phase 3 program, MMPOWER-3, evaluated elamipretide in primary mitochondrial myopathy (NCT03323749). Its double-blind portion failed to meet either primary endpoint: six-minute walk distance and fatigue score improved similarly in both the elamipretide and placebo groups. Negative or inconclusive trial history is still part of the evidence base.

Other elamipretide programs continue too, including an active Phase 3 study in dry age-related macular degeneration. Together, these elamipretide clinical trials show a compound that has progressed through multiple stages of clinical development.

For more on the underlying mechanism, see our SS-31 mitochondrial research profile.

BPC-157: What Human and Registered Trial Evidence Exists?

As of the current registry check, ClinicalTrials.gov lists a Phase 2 BPC-157 study, NCT07437547– BPC 157 for Acute Hamstring Muscle Strain Repair. Its current status is recruiting, with no results posted.

Among BPC-157 clinical trials, a recruiting record means a study is registered and underway. It doesn’t provide completed outcome evidence. That distinction is important when evaluating BPC-157 clinical evidence, safety claims, and regulatory status, because trial registration alone does not answer any of those questions.

Separately, a small 2025 pilot report evaluated intravenous BPC-157 safety in just two participants, with no adverse effects reported (PubMed). That’s genuine human evidence, but its scale means it can’t stand in for a randomized, adequately powered trial or establish broad safety and efficacy.

For more background, see our BPC-157 research primer and our overview of BPC-157’s research areas, risks, and legal considerations.

MOTS-c: Human Observation vs. Interventional Trial Data

MOTS-c shows why evidence-category distinctions matter. Older human studies measured circulating endogenous MOTS-c in metabolic research, exercise, and disease cohorts. That work is genuine human research, but it measured the body’s own MOTS-c rather than testing it as an administered drug.

That’s different from the current MOTS-c clinical trial on ClinicalTrials.gov: NCT07505745, MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity. Its status is Phase 2a and recruiting, with no results posted yet.

A registered, recruiting study establishes clinical-development activity, not clinical efficacy. Its outcomes aren’t known yet, and shouldn’t be described as if they were.

KPV: Is There a Registered Human Clinical Trial?

At the time of this registry review, no verified ClinicalTrials.gov interventional study named KPV as the administered peptide. That includes a check under the name Lys-Pro-Val. This finding is narrower than saying “KPV has never been studied in humans.” A broader global literature and registry search would be needed to support that stronger claim.

A clinical trials KPV peptide search should include multiple naming variants: KPV, Lys-Pro-Val, lysine-proline-valine, and α-MSH fragment KPV.

If no relevant record is identified across those variants, the article should report that no verified ClinicalTrials.gov intervention record was found.

For more background, see our KPV research overview and introduction to the KPV fragment.

What About TB-500, GHK-Cu, and Other Common Research Peptides?

Several additional compounds require more careful identity-based verification because related molecules can appear under different registry names.

TB-500 vs. thymosin β4. A registry search for thymosin β4 turns up multiple registered trials, including RegeneRx’s RGN-352 and Beijing Northland’s NL005 programs, none registered under the name TB-500. A trial involving full thymosin β4 doesn’t establish clinical trial data for the TB-500 fragment. The exact intervention studied has to match the peptide being discussed.

GHK-Cu. Searches should cover GHK-Cu, copper tripeptide, copper peptide, and GHK copper, with results inspected manually, since “GHK” can surface unrelated acronyms.

CJC-1295 and ipamorelin. Clinical development shouldn’t be inferred from growth-hormone secretagogue research generally. Each compound needs its own intervention-level search rather than borrowing status from a related class.

What’s the Difference Between Preclinical, Phase 1, Phase 2, Phase 3, and Completed Trial Data?

Stage / Status	What it actually means
Preclinical research	Laboratory or nonhuman research before or alongside human development
Phase 1	Initial human studies focused primarily on safety, tolerability, pharmacology, and pharmacokinetics
Phase 2	Studies evaluating preliminary effectiveness while continuing to assess safety
Phase 3	Larger confirmatory studies designed to evaluate effectiveness and safety more definitively
Recruiting	Trial is currently seeking participants
Active, not recruiting	Trial is ongoing but enrollment has closed
Completed	Trial activities have ended according to the study record
Terminated	Trial stopped early
Results posted	Structured results are available on the registry
Published	Results have appeared in a scientific publication

The FDA describes clinical development as progressing through these phases, with different objectives and enrollment sizes at each stage. “Completed” doesn’t mean “results published,” either. ClinicalTrials.gov distinguishes a study’s recruitment and completion status from whether results have actually been posted.

Why Trial Phase Alone Doesn’t Tell You Whether a Peptide “Works”

No. Trial registration, or advancement to a particular phase, doesn’t by itself establish efficacy or safety. Phase identifies a development stage, not a result. Recruiting studies have no completed outcome data, trials can fail their primary endpoints, and results can stay unpublished long after a study finishes.

Elamipretide illustrates this well. It has a substantial clinical-development history, including completed and posted results, yet its MMPOWER-3 Phase 3 program didn’t meet its primary endpoints. That’s why “has clinical trials” shouldn’t be translated into “clinically proven,” for elamipretide or any other compound.

Registered Trial vs. Published Trial: Why the Difference Matters

For peptides in clinical trials, a ClinicalTrials.gov record shows sponsor, intervention, phase, recruitment status, enrollment, and results status. A journal publication adds methods, statistics, outcome interpretation, and peer review.

Neither substitutes for the other. A registry entry can exist without a published paper, and a paper can describe research that was never a randomized drug trial.

Where Can Researchers Verify Clinical Trial Records?

ClinicalTrials.gov is the primary source for verifying NCT numbers, interventions, sponsors, phases, and results status. Its guide to reading a study record explains how to interpret those fields.

PubMed helps locate peer-reviewed publications tied to a compound, trial identifier, or development name. For compounds developed outside the United States, check regional registries or the WHO International Clinical Trials Registry Platform too.

How to Verify a Peptide Trial Claim

The following checks help determine whether a clinical-trial claim is accurately characterized:

1. What exact peptide was studied?
2. Was it the intervention, or only measured as a biomarker?
3. Was the study interventional or observational?
4. Was it registered?
5. What phase was it?
6. What is its current status?
7. Are results posted?
8. Is there a peer-reviewed publication?
9. Did the study meet its primary endpoint?
10. Is the trial about the exact compound, not a parent molecule, analog, or fragment?

Running through those ten questions turns a vague claim about research peptides human trials into something checkable.

Research Status Is Not Regulatory Status

For peptides in clinical trials, registration doesn’t equal FDA approval. Reaching Phase 3 doesn’t equal approval, and human evidence alone doesn’t equal approval either. A compound can accumulate meaningful peptide clinical trial data for years without reaching an approved product. Approved status always has to be checked separately against FDA sources.

What the Current Evidence Landscape Shows

Peptides in clinical trials occupy very different evidence stages, and that spread is the main thing this overview establishes.

• SS-31/elamipretide has a comparatively mature clinical-development history, including completed studies with posted results and a terminated Phase 3 program.
• BPC-157 now has a registered Phase 2 study, but completed controlled trial results remain unavailable from it.
• MOTS-c has entered registered interventional development, while older human MOTS-c research often involved measurement rather than administration.
• KPV currently lacks a verified registered intervention trial in the registry search used here.
• Registration, completion, posted results, and peer-reviewed publication are separate milestones, not synonyms.
• Exact intervention identity matters whenever peptide names, parent molecules, fragments, and development names overlap.

None of that ranks which peptide is “best” or “most proven.” It’s simply where the documented status of peptides in clinical trials currently stands, subject to change as registries update.

---

Frequently Asked Questions